The DOI matches its Crossref record, with a small difference in title or year; 251 of the 252 references it cites were found in a registry or an index.
Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy
Open accessAbstract
Hypertrophic cardiomyopathy (HCM) is a genetic disorder that is characterized by left ventricular hypertrophy unexplained by secondary causes and a nondilated left ventricle with preserved or increased ejection fraction. It is commonly asymmetrical with the most severe hypertrophy involving the basal interventricular septum. Left ventricular outflow tract obstruction is present at rest in about one third of the patients and can be provoked in another third. The histological features of HCM include myocyte hypertrophy and disarray, as well as interstitial fibrosis. The hypertrophy is also frequently associated with left ventricular diastolic dysfunction. In the majority of patients, HCM has a relatively benign course. However, HCM is also an important cause of sudden cardiac death, particularly in adolescents and young adults. Nonsustained ventricular tachycardia, syncope, a family history of sudden cardiac death, and severe cardiac hypertrophy are major risk factors for sudden cardiac death. This complication can usually be averted by implantation of a cardioverter-defibrillator in appropriate high-risk patients. Atrial fibrillation is also a common complication and is not well tolerated. Mutations in over a dozen genes encoding sarcomere-associated proteins cause HCM. MYH7 and MYBPC3 , encoding β-myosin heavy chain and myosin-binding protein C, respectively, are the 2 most common genes involved, together accounting for ≈50% of the HCM families. In ≈40% of HCM patients, the causal genes remain to be identified. Mutations in genes responsible for storage diseases also cause a phenotype resembling HCM (genocopy or phenocopy). The routine applications of genetic testing and preclinical identification of family members represents an important advance. The genetic discoveries have enhanced understanding of the molecular pathogenesis of HCM and have stimulated efforts designed to identify new therapeutic agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This clinical variability can, in part, be explained by the influence of modifiable cardiometabolic risk factors, such as obesity, diabetes, and hypertension [6].”
From Association of GLP-1 receptor agonist use with cardiovascular outcomes in patients with non-obstructive hypertrophic cardiomyopathy (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredIn the citing paper
“Hypertrophic cardiomyopathy (HCM) is characterized by cardiac hypertrophy, a non-dilated left ventricle (LV), and a normal or increased EF.”
From Cardiovascular disease models: A game changing paradigm in drug discovery and screening (2019) · cites this paper as [52]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A global reference for human genetic variation
The 1000 Genomes Project Consortium, authors, C., Auton, A., Abecasis, G. R., Steering committee, Altshuler, D. M., Durbin, R. M., Abecasis, G. R., Bentley, D. R., Chakravarti, A., et al. (2015) · Nature · doi:10.1038/nature15393 · Cited by 18,247
A map of human genome variation from population-scale sequencing.
The 1000 Genomes Project Consortium (2010) · Nature · doi:10.1038/nature09534 · Cited by 7,877
2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy
Authors/Task Force members, Elliott, P. M., Anastasakis, A., Borger, M. A., Borggrefe, M., Cecchi, F., Charron, P., Hagege, A. A., Lafont, A., Limongelli, G., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu284 · Cited by 4,332
Prevalence of Hypertrophic Cardiomyopathy in a General Population of Young Adults
Maron, B. J., Gardin, J. M., Flack, J. M., Gidding, S. S., Kurosaki, T., & Bild, D. E. (1995) · Circulation · doi:10.1161/01.cir.92.4.785 · Cited by 2,274
Sudden Deaths in Young Competitive Athletes
Maron, B. J., Doerer, J. J., Haas, T. S., Tierney, D. M., & Mueller, F. O. (2009) · Circulation · doi:10.1161/circulationaha.108.804617 · Cited by 2,099
Sudden Death in Young Competitive Athletes: Clinical, Demographic, and Pathological Profiles
Maron, B. J. (1996) · JAMA · doi:10.1001/jama.1996.03540030033028 · Cited by 1,693
New Perspectives on the Prevalence of Hypertrophic Cardiomyopathy
Semsarian, C., Ingles, J., Maron, M. S., & Maron, B. J. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.01.019 · Cited by 1,405
Geisterfer-Lowrance, A. A. T., Kass, S., Tanigawa, G., Vosberg, H.-P., McKenna, W., Seidman, C. E., & Seidman, J. G. (1990) · Cell · doi:10.1016/0092-8674(90)90274-i · Cited by 1,380
Richard, P., Charron, P., Carrier, L., Ledeuil, C., Cheav, T., Pichereau, C., Benaiche, A., Isnard, R., Dubourg, O., Burban, M., et al. (2003) · Circulation · doi:10.1161/01.cir.0000066323.15244.54 · Cited by 1,276
O'Mahony, C., Jichi, F., Pavlou, M., Monserrat, L., Anastasakis, A., Rapezzi, C., Biagini, E., Gimeno, J. R., Limongelli, G., McKenna, W. J., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/eht439 · Cited by 1,251
Research works printed but not linked: 2
- 10.1161/01.CIR.104.3.317 · DOI
- BROCK R. Functional obstruction of the left ventricle (acquired aortic subvalvar stenosis). Guys Hosp Rep. 1959;108:126–143.
Cited by
Sorted by citations
Items 101–200 of 1,001
Wilcox, J. E., & Hershberger, R. E. (2018) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000512 · Cited by 58
hiPSC-Derived Cardiac Tissue for Disease Modeling and Drug Discovery
Li, J., Hua, Y., Miyagawa, S., Zhang, J., Li, L., Liu, L., & Sawa, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238893 · Cited by 56
Left Ventricular Hypertrophy: Etiology-Based Therapeutic Options
Sayın, B. Y., & Oto, A. (2022) · Cardiology and Therapy · doi:10.1007/s40119-022-00260-y · Cited by 60
Huang, L., Ran, L., Zhao, P., Tang, D., Han, R., Ai, T., Xia, L., & Tao, Q. (2019) · British Journal of Radiology · doi:10.1259/bjr.20190634 · Cited by 54
Personalized medicine for cardiovascular diseases
Tada, H., Fujino, N., Nomura, A., Nakanishi, C., Hayashi, K., Takamura, M., & Kawashiri, M. (2020) · Journal of Human Genetics · doi:10.1038/s10038-020-0818-7 · Cited by 57
Artificial Intelligence in Cardiovascular Medicine: Current Insights and Future Prospects
Haq, I. U., Chhatwal, K., SANAKA, K. O., & Xu, B. (2022) · Vascular Health and Risk Management · doi:10.2147/vhrm.s279337 · Cited by 65
Ho, B. X., Pang, J. K. S., Phua, Q. H., Liew, L. C., Poh, B. M., Chen, Y., Loh, Y.-H., An, Ö., Yang, H. H., Seshachalam, V. P., et al. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-03215-1 · Cited by 60
Meng, Q., Bhandary, B., Bhuiyan, M. S., James, J., Osińska, H. E., Valiente-Alandí, Í., Shay‐Winkler, K., Gulick, J. M., Molkentin, J. D., Blaxall, B. C., et al. (2018) · Circulation Research · doi:10.1161/circresaha.118.313089 · Cited by 52
Inhibiting cardiac myeloperoxidase alleviates the relaxation defect in hypertrophic cardiomyocytes
Ramachandra, C. J. A., Ja, K. P. M. M., Chua, J., Hernández‐Reséndiz, S., Liehn, E. A., Knöll, R., Gan, L., Michaëlsson, E., Jonsson, M. K. B., Rydén‐Markinhuhta, K., et al. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab077 · Cited by 53
Myocardial Perfusion Defects in Hypertrophic Cardiomyopathy Mutation Carriers
Hughes, R. K., Camaioni, C., Augusto, J. B., Knott, K. D., Quinn, E., Captur, G., Seraphim, A., Joy, G., Syrris, P., Elliot, P. M., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.020227 · Cited by 52
Inchingolo, A. V., Previs, S. B., Previs, M. J., Warshaw, D. M., & Kad, N. M. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1816480116 · Cited by 52
Pelliccia, F., Alfieri, O., Calabrò, P., Cecchi, F., Ferrazzi, P., Gragnano, F., Kaski, J. P., Limongelli, G., Maron, M. S., Rapezzi, C., et al. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.01.021 · Cited by 52
Genetics of Cardiomyopathy: Clinical and Mechanistic Implications for Heart Failure
Kim, K., & Pereira, N. L. (2021) · Korean Circulation Journal · doi:10.4070/kcj.2021.0154 · Cited by 55
Genomic Autopsy of Sudden Deaths in Young Individuals
Webster, G., Puckelwartz, M. J., Pesce, L. L., Dellefave‐Castillo, L. M., Vanoye, C. G., Potet, F., Page, P., Kearns, S. D., Pottinger, T. D., White, S., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2021.2789 · Cited by 51
DeepStrain: A Deep Learning Workflow for the Automated Characterization of Cardiac Mechanics
Morales, M. A., van den Boomen, M., Nguyen, C. T., Kalpathy–Cramer, J., Rosen, B. R., Stultz, C. M., Izquierdo‐Garcia, D., & Catana, C. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.730316 · Cited by 51
Peikert, A., Fontana, M., Solomon, S. D., & Thum, T. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf524 · Cited by 61
Dynamic Left Intraventricular Obstruction Phenotype in Takotsubo Syndrome
Vece, D. D., Silverio, A., Bellino, M., Galasso, G., Vecchione, C., Canna, G. L., & Citro, R. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10153235 · Cited by 51
Recent advancements and applications of deep learning in heart failure: Α systematic review
Πετμεζάς, Γ., Papageorgiou, V. Ε., Vassilikos, V. P., Pagourelias, E. D., Tsaklidis, G. M., Katsaggelos, A. K., & Maglaveras, N. (2024) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2024.108557 · Cited by 53
Forrest, I. S., Rocheleau, G., Bafna, S., Argulian, E., Narula, J., Natarajan, P., & Do, R. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2482 · Cited by 50
Ethnicity, consanguinity, and genetic architecture of hypertrophic cardiomyopathy
Allouba, M., Walsh, R., Afify, A., Hosny, M., Halawa, S., Galal, A. A., Fathy, M., Theotokis, P. I., Boraey, A., Ellithy, A., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad372 · Cited by 48
Apical Ischemia Is a Universal Feature of Apical Hypertrophic Cardiomyopathy
Hughes, R. K., Augusto, J. B., Knott, K. D., Davies, R. H., Shiwani, H., Seraphim, A., Malcolmson, J. W., Khoury, S., Joy, G., MOHIDDIN, S. A., et al. (2023) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.122.014907 · Cited by 47
Genetic basis and molecular biology of cardiac arrhythmias in cardiomyopathies
Marian, A. J., Asatryan, B., & Wehrens, X. H. T. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa116 · Cited by 49
Self-citationHeinzel, F. R., Hegemann, N., Hohendanner, F., Primeßnig, U., Grune, J., Blaschke, F., de Boer, R. A., Pieske, B. M., Schiattarella, G. G., & Kuebler, W. M. (2020) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt-20-477 · Cited by 49
2020 Clinical practice guidelines for Hypertrophic cardiomyopathy
Габрусенко, С. А., Gudkova, A. Y., Koziolova, N. A., Alexandrova, S. А., Berseneva, M., Гордеев, М. Л., Sl, D., Zaklyazminskaya, E. V., Irtyuga, O. B., Kaplunova, V. Y., et al. (2021) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2021-4541 · Cited by 56
Efficient Correction of a Hypertrophic Cardiomyopathy Mutation by ABEmax-NG
Ma, S., Jiang, W., Liu, X., Lu, W., Qi, T., Wei, J., Wu, F., Chang, Y., Zhang, S., Song, Y., et al. (2021) · Circulation Research · doi:10.1161/circresaha.120.318674 · Cited by 45
Risk factors of sudden cardiac death in hypertrophic cardiomyopathy
Hong, Y., SU, W. W., & Li, X. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000939 · Cited by 46
Cardiomyocyte-GSK-3α promotes mPTP opening and heart failure in mice with chronic pressure overload
Ahmad, F., Singh, A. P., Tomar, D., Rahmani, M., Zhang, Q., Woodgett, J. R., Tilley, D. G., Lal, H., & Force, T. L. (2019) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2019.03.020 · Cited by 48
Hypertrophic Cardiomyopathy—Past, Present and Future
Liew, A. C., Vassiliou, V. S., Cooper, R. M., & Raphael, C. E. (2017) · Journal of Clinical Medicine · doi:10.3390/jcm6120118 · Cited by 45
Li, S., Peng, B., Luo, X., Sun, H., & Peng, C. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14181 · Cited by 45
Snoberger, A. M., Barua, B., Atherton, J. L., Shuman, H., Forgacs, E., Goldman, Y. E., Winkelmann, D. A., & Ostap, E. M. (2021) · eLife · doi:10.7554/elife.63691 · Cited by 45
Recent progress of iPSC technology in cardiac diseases
Funakoshi, S., & Yoshida, Y. (2021) · Archives of Toxicology · doi:10.1007/s00204-021-03172-3 · Cited by 47
Single-nucleus transcriptomics reveals a gatekeeper role for FOXP1 in primate cardiac aging
Zhang, Y., Zheng, Y., Wang, S., Fan, Y., Ye, Y., Jing, Y., Liu, Z., Yang, S., Xiong, M., Yang, K., et al. (2022) · Protein & Cell · doi:10.1093/procel/pwac038 · Cited by 45
Cardiac Myosin Inhibitors for Managing Obstructive Hypertrophic Cardiomyopathy
Ostrominski, J. W., Guo, R., Elliott, P. M., & Ho, C. Y. (2023) · JACC: Heart Failure · doi:10.1016/j.jchf.2023.04.018 · Cited by 42
Li, S., Zhang, C., Liu, N., Bai, H., Hou, C., Wang, J., Song, L., & Pu, J. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.009910 · Cited by 44
Gene therapy for inherited arrhythmias
Bezzerides, V. J., Prondzynski, M., Carrier, L., & Pu, W. T. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa107 · Cited by 45
Aung, L. H. H., Jumbo, J. C. C., Wang, Y., & Li, P. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.06.006 · Cited by 45
Laboratory medicine: health evaluation in elite athletes
Lombardo, B., Izzo, V., Terracciano, D., Ranieri, A., Mazzaccara, C., Fimiani, F., Cesaro, A., Gentile, L., Leggiero, E., Pero, R., et al. (2019) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2018-1107 · Cited by 46
Long-term outcomes of childhood onset Noonan compared to sarcomere hypertrophic cardiomyopathy
Kaltenecker, E., Schleihauf, J., Meierhofer, C., Shehu, N., Mkrtchyan, N., Hager, A., Kühn, A., Cleuziou, J., Klingel, K., Seidel, H., et al. (2019) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2019.05.01 · Cited by 43
Vio, R., Angelini, A., Basso, C., Cipriani, A., Zorzi, A., Melacini, P., Thiene, G., Rampazzo, A., Corrado, D., & Calore, C. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10091954 · Cited by 45
Cardiomyocyte Proliferation from Fetal- to Adult- and from Normal- to Hypertrophy and Failing Hearts
Bishop, S. P., Zhang, J. J., & Ye, L. (2022) · Biology · doi:10.3390/biology11060880 · Cited by 46
Structural and signaling proteins in the Z-disk and their role in cardiomyopathies
Noureddine, M., & Gehmlich, K. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1143858 · Cited by 47
Apical hypertrophic cardiomyopathy: pathophysiology, diagnosis and management
Li, J., Fang, J., Liu, Y., & Wei, X. (2023) · Clinical Research in Cardiology · doi:10.1007/s00392-023-02328-8 · Cited by 44
Jolfayi, A. G., Kohansal, E., Ghasemi, S., Naderi, N., Hesami, M., MozafaryBazargany, M., Moghadam, M. H., Fazelifar, A. F., Maleki, M., & Kalayinia, S. (2024) · Scientific Reports · doi:10.1038/s41598-024-56154-7 · Cited by 41
Yadav, S. K., Sitbon, Y. H., Kaźmierczak, K., & Szczesna‐Cordary, D. (2019) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-019-02257-4 · Cited by 42
Right ventricular involvement in hypertrophic cardiomyopathy: Patterns and implications
Keramida, K., Lazaros, G. A., & Nihoyannopoulos, P. (2018) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2018.11.009 · Cited by 41
Implantable defibrillators in primary prevention of genetic arrhythmias. A shocking choice?
Corrado, D., Link, M. S., & Schwartz, P. J. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac298 · Cited by 41
MDM2 Regulation of HIF Signaling Causes Microvascular Dysfunction in Hypertrophic Cardiomyopathy
Shridhar, P., Glennon, M. S., Pal, S., Waldron, C. J., Chetkof, E. J., Basak, P., Clavere, N. G., Banerjee, D., Gingras, S., & Becker, J. R. (2023) · Circulation · doi:10.1161/circulationaha.123.064332 · Cited by 42
Emerging risk factors for heart failure in younger populations: A growing public health concern
Parizad, R., Batta, A., Hatwal, J., Sadeghi, M. T., & Mohan, B. (2025) · World Journal of Cardiology · doi:10.4330/wjc.v17.i4.104717 · Cited by 43
Myocardial Energy Metabolism in Non-ischemic Cardiomyopathy
Greenwell, A. A., Gopal, K., & Ussher, J. R. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.570421 · Cited by 42
Zhang, B., Tan, Y., Zhang, Z., Feng, P., Ding, W., Wang, Q., Liang, H., Duan, W., Wang, X., Yu, S., et al. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/9187065 · Cited by 40
Endogenous T1ρ cardiovascular magnetic resonance in hypertrophic cardiomyopathy
Thompson, E. W., Iyer, S. K., Solomon, M. P., Li, Z., Zhang, Q., Piechnik, S. K., Werys, K., Swago, S., Moon, B. F., Rodgers, Z. B., et al. (2021) · Journal of Cardiovascular Magnetic Resonance · doi:10.1186/s12968-021-00813-5 · Cited by 40
Hypertrophic Cardiomyopathy: From Phenotype and Pathogenesis to Treatment
Cheng, Z., Fang, T., Huang, J., Guo, Y., Alam, M., & Qian, H. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.722340 · Cited by 40
MEF2 in cardiac hypertrophy in response to hypertension
Cornwell, J. D., & McDermott, J. C. (2022) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2022.01.002 · Cited by 43
Global PIEZO1 Gain-of-Function Mutation Causes Cardiac Hypertrophy and Fibrosis in Mice
Bartoli, F., Evans, E. L., Blythe, N. M., Stewart, L., Chuntharpursat‐Bon, E., Debant, M., Musialowski, K. E., Lichtenstein, L., Parsonage, G., Futers, T. S., et al. (2022) · Cells · doi:10.3390/cells11071199 · Cited by 39
A systematic review of microRNAs in patients with hypertrophic cardiomyopathy
Scolari, F. L., Faganello, L. S., Garbin, H. I., Mattos, B. P. E., & Biolo, A. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.11.004 · Cited by 39
Sewanan, L. R., & Campbell, S. G. (2019) · The Journal of Physiology · doi:10.1113/jp276753 · Cited by 38
Sakaguchi, T., Takefuji, M., Wettschureck, N., Hamaguchi, T., Amano, M., Kato, K., Tsuda, T., Eguchi, S., Ishihama, S., Mori, Y., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.041019 · Cited by 38
The pig as an optimal animal model for cardiovascular research
Jia, H., Chang, Y., & Song, J. (2024) · Lab Animal · doi:10.1038/s41684-024-01377-4 · Cited by 41
Atrial fibrillation in patients with inherited cardiomyopathies
Yeung, C., Enriquez, A. A., Suarez‐Fuster, L., & Baranchuk, A. M. (2018) · EP Europace · doi:10.1093/europace/euy064 · Cited by 37
van den Brink, L., Grandela, C., Mummery, C. L., & Davis, R. P. (2019) · Stem Cells · doi:10.1002/stem.3110 · Cited by 36
Suzuki, K., Miyagawa, S., Liu, L., Kawamura, T., Li, J., Qu, X., Harada, A., Toda, K., Yoshioka, D., Kainuma, S., et al. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.04.010 · Cited by 37
Myofibril orientation as a metric for characterizing heart disease
Ma, W., Gong, H. M., Jani, V., Lee, K. H., Landim-Vieira, M., Papadaki, M., Pinto, J. R., Aslam, M., Cammarato, A., & Irving, T. C. (2022) · Biophysical Journal · doi:10.1016/j.bpj.2022.01.009 · Cited by 37
Li, J., Feng, X., & Wei, X. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-02905-0 · Cited by 42
Molecular Diagnosis of Hypertrophic Cardiomyopathy (HCM): In the Heart of Cardiac Disease
Melas, M., Beltsios, E. T., Adamou, A., Koumarelas, K. E., & McBride, K. L. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm12010225 · Cited by 37
Novel approaches to target fibroblast mechanotransduction in fibroproliferative diseases
Ezzo, M., & Hinz, B. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108528 · Cited by 39
Gene therapy for cardiac diseases: methods, challenges, and future directions
Grisorio, L., Bongianino, R., Gianeselli, M., & Priori, S. G. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae207 · Cited by 36
Exploring the Continuum of Hypertrophic Cardiomyopathy—From DNA to Clinical Expression
Popa‐Fotea, N., Micheu, M. M., Bătăilă, V., Scafa‐Udriște, A., Dorobantu, L. F., Scărlătescu, A. I., Zamfir, D., Stoian, M., Onciul, S., & Dorobanţu, M. (2019) · Medicina · doi:10.3390/medicina55060299 · Cited by 39
Korthals, D., Chatzantonis, G., Bietenbeck, M., Meier, C., Stalling, P., & Yılmaz, A. (2021) · Scientific Reports · doi:10.1038/s41598-021-94650-2 · Cited by 36
Understanding the molecular basis of cardiomyopathy
Bang, M., Bogomolovas, J., & Chen, J. (2021) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00562.2021 · Cited by 37
Thottakara, T., Lund, N., Krämer, E., Kirchhof, P. F., Carrier, L., & Patten, M. (2021) · Biomolecules · doi:10.3390/biom11111718 · Cited by 36
Lumican Accumulates with Fibrillar Collagen in Fibrosis in Hypertrophic Cardiomyopathy
Rixon, C., Andreassen, K. E., Shen, X. M., Erusappan, P. M., Almaas, V. M., Palmero, S., Dahl, C. P., Ueland, T., Sjaastad, I., Louch, W. E., et al. (2022) · ESC Heart Failure · doi:10.1002/ehf2.14234 · Cited by 36
Krause, U., Müller, M. J., Wilberg, Y., Pietzka, M., Backhoff, D., Ruschewski, W., & Paul, T. (2018) · EP Europace · doi:10.1093/europace/euy219 · Cited by 35
Schipper, T., Poucke, M. V., Sonck, L., Smets, P. M. Y., Ducatelle, R., Broeckx, B. J. G., & Peelman, L. J. (2019) · European Journal of Human Genetics · doi:10.1038/s41431-019-0431-4 · Cited by 35
Pathobiology of cardiovascular diseases: an update
Buja, L. M., Giulia Ottaviani, M., & Mitchell, R. N. (2019) · Cardiovascular Pathology · doi:10.1016/j.carpath.2019.06.002 · Cited by 37
Gudmundsdottir, H. L., Raja, A. A., Rossing, K., Rasmusen, H. K., Snoer, M., Andersen, L. J., Gottlieb, R., Christensen, A. H., Bundgaard, H., Gustafsson, F., et al. (2024) · Circulation · doi:10.1161/circulationaha.124.070064 · Cited by 33
Georgiopoulos, G. A., Figliozzi, S., Pateras, K., Nicoli, F., Bampatsias, D., Beltrami, M., Finocchiaro, G., Chiribiri, A., Masci, P. G., & Olivotto, I. (2022) · JACC Heart Failure · doi:10.1016/j.jchf.2022.08.022 · Cited by 33
Yang, X., Li, X., Yu, N. H., Yan, R., Sun, Y., Tang, C.-M., Ding, W., Ling, M., Song, Y., Gao, H., et al. (2023) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2023.100659 · Cited by 36
Miller, R., Kerfoot, E., Mauger, C., Ismail, T. F., Young, A. A., & Nordsletten, D. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.716597 · Cited by 36
Wang, Y., Han, J., Zhan, S.-Z., Guo, C., Yin, S., Zhan, L., Zhou, Q., Liu, R., Yan, H., Wang, X., et al. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.133792 · Cited by 32
Hypertrophic Obstructive Cardiomyopathy
Batzner, A., Schäfers, H., Borisov, K. V., & Seggewiß, H. (2019) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2019.0047 · Cited by 33
Autosomal recessive cardiomyopathy and sudden cardiac death associated with variants in MYL3
Osborn, D. P. S., Emrahi, L., Clayton, J. S., Toufan, M., Wan, A. Y. B., Maroofian, R., Yazdchi, M. R., Garcia, M. L. E., Galehdari, H., Hesse, C., et al. (2020) · Genetics in Medicine · doi:10.1038/s41436-020-01028-2 · Cited by 32
Yu, F., Huang, H., Yu, Q., Ma, Y., Zhang, Q., & Zhang, B. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-4891 · Cited by 32
Finocchiaro, G., Sheikh, N., Leone, O., Westaby, J. D., Mazzarotto, F., Pantazis, A. A., Ferrantini, C., Sacconi, L., Papadakis, M., Sharma, S., et al. (2020) · EP Europace · doi:10.1093/europace/euaa348 · Cited by 35
Precision Medicine in Cardiovascular Disease: Genetics and Impact on Phenotypes
Semsarian, C., Ingles, J., Ross, S. B., Dunwoodie, S. L., Bagnall, R. D., & Kovacic, J. C. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.12.071 · Cited by 38
Hsieh, J., Becklin, K. L., Givens, S. E., Komosa, E. R., Abrahante, J. E., Kamdar, F. D., Moriarity, B. S., Webber, B. R., Singh, B. N., & Ogle, B. M. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.894635 · Cited by 32
Contemporary Therapies and Future Directions in the Management of Hypertrophic Cardiomyopathy
Packard, E., de Feria, A., Peshin, S., Reza, N., & OWENS, A. T. (2022) · Cardiology and Therapy · doi:10.1007/s40119-022-00283-5 · Cited by 32
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022
Tamargo, J. L., Agewall, S., Borghi, C., Ceconi, C., Cerbai, E., Dan, G. A., Ferdinandy, P., Grove, E. L., Rocca, B., Sulzgruber, P., et al. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad034 · Cited by 33
iPSC-Based Modeling of Variable Clinical Presentation in Hypertrophic Cardiomyopathy
Escribá, R., Larrañaga-Moreira, J. M., Richaud‐Patín, Y., Pourchet, L., Lazis, I., Jiménez‐Delgado, S., Morillas-García, A., Ortiz-Genga, M., Ochoa, J. P., Carreras, D., et al. (2023) · Circulation Research · doi:10.1161/circresaha.122.321951 · Cited by 36
Hypertrophic Cardiomyopathy: Genetic Foundations, Outcomes, Interconnections, and Their Modifiers
Glavaški, M., Velicki, L., & Vučinić, N. (2023) · Medicina · doi:10.3390/medicina59081424 · Cited by 33
Ning, C., Fan, L., Jin, M., Wang, W., Hu, Z., Cai, Y., Chen, L., Lu, Z., Zhang, M., Chen, C., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43771-5 · Cited by 31
OWENS, A. T., Desai, M. Y., Wheeler, M. T., Rodonski, A., Merali, S. J., Sehnert, A. J., & Saberi, S. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.124.033767 · Cited by 31
Choi, S. H., Jurgens, S. J., Xiao, L., Hill, M. C., Haggerty, C. M., Sveinbjörnsson, G., Morrill, V. N., Marston, N., Weng, L.-C. C., Pirruccello, J. P., et al. (2025) · Nature Genetics · doi:10.1038/s41588-025-02074-9 · Cited by 34
Meurs, K. M., Williams, B. G., DeProspero, D. J., Friedenberg, S. G., Malarkey, D. E., Ezzell, J. A., Keene, B. W., Adin, D. B., DeFrancesco, T. C., & Tou, S. P. (2021) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-021-01740-5 · Cited by 31
Sahiti, F., Morbach, C., Cejka, V., Albert, J., Eichner, F. A., Gelbrich, G., Heuschmann, P. U., & Störk, S. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.669335 · Cited by 31
Sewanan, L. R., Park, J., Rynkiewicz, M. J., Racca, A. W., Papoutsidakis, N., Schwan, J., Jacoby, D. L., Moore, J. R., Lehman, W., Qyang, Y., et al. (2021) · The Journal of General Physiology · doi:10.1085/jgp.202012640 · Cited by 31
Zhang, X., Zhang, S., Tang, T., & Cheng, X. C. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.696321 · Cited by 30
The mechanics of the heart: zooming in on hypertrophic cardiomyopathy and cMyBP‐C
Suay‐Corredera, C., & Alegre‐Cebollada, J. (2022) · FEBS Letters · doi:10.1002/1873-3468.14301 · Cited by 31
Altered force generation and cell-to-cell contractile imbalance in hypertrophic cardiomyopathy
Kraft, T., & Montag, J. (2019) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-019-02260-9 · Cited by 29
Magadum, A., Singh, N., Kurian, A. A., Sharkar, M. T. K., Sultana, N., Chepurko, E., Kaur, K., Żak, M. M., Hadas, Y., Lebeche, D., et al. (2021) · Advanced Science · doi:10.1002/advs.202004661 · Cited by 30
Update on the Diagnostic Pitfalls of Autopsy and Post-Mortem Genetic Testing in Cardiomyopathies
Grassi, S., Campuzano, Ó., Coll, M., Cazzato, F., Sarquella‐Brugada, G., Rossi, R., Arena, V., Brugada, J., Brugada, R., & Oliva, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084124 · Cited by 30
Metadata
- Authors
- Marian, A. J., & Braunwald, E.
- Affiliations
- Brigham and Women's Hospital (US)
- From the Center for Cardiovascular Genetics, Institute of Molecular Medicine, Department of Medicine, University of Texas Health Sciences Center at Houston (A.J.M.); Texas Heart Institute, Houston (A.J.M.); and TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA (E.B.).
- ORCID
- Marian, Ali J.
- Venue
- Circulation Research
- Published
- 2017-09-15
- Volume
- 121
- Issue
- 7
- Pages
- 749-770
- ISSN
- 0009-7330 (ISSN-L)
- 1524-4571
- PMC
- PMC5654557
- OpenAlex
- W2756203218
- Cited by
- 1,403
- References
- 252
- Citations by year
- 2026: 175 · 2025: 226 · 2024: 219 · 2023: 199 · 2022: 153 · 2021: 174 · 2020: 103 · 2019: 83 · 2018: 61 · 2017: 6
- FWCI
- 9.75
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Circulation Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL088498, R01HL132401)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiomyopathy and Myosin Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Effects of Exercise
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Keywords
- hypertrophic cardiomyopathy, left ventricular hypertrophy, left ventricular outflow tract obstruction, sudden cardiac death, non-sustained ventricular tachycardia, syncope, cardioverter-defibrillator implantation, atrial fibrillation, sarcomere gene mutations, MYH7, MYBPC3, genetic testing, phenocopy, storage diseases, left ventricular diastolic dysfunction, interstitial fibrosis, molecular pathogenesis
- MeSH terms
- Animals, Biopsy, Cardiomyopathy, Dilated, DNA Mutational Analysis, Genetic Markers, Humans, Mutation, Myocardium, Phenotype, Predictive Value of Tests, Prognosis, Risk Factors, Ventricular Function, Left, Risk Assessment, Genetic Predisposition to Disease, Molecular Diagnostic Techniques, Cardiac Imaging Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
